Fasenra (benralizumab)

Fasenra (benralizumab) is covered only as the FDA‑approved add‑on maintenance treatment for severe eosinophilic asthma in patients ≥12 years and is not covered for patients <12 or for non‑FDA indications (e.g., COPD, hypereosinophilic syndromes). Coverage requires blood eosinophils ≥150 cells/µL within 6 weeks (or documented prior to other eosinophil‑lowering mAb), ≥3 months of an inhaled corticosteroid plus another controller, evidence of uncontrolled asthma by exacerbations or spirometry, prescription by or consult with an allergist/immunologist/pulmonologist, initial approval for 6 months and renewal (12 months) only after ≥6 months of Fasenra with documented clinical response.

"Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype."

Sign up to see full coverage criteria, indications, and limitations.